2230 GMT - CSL's vaccines business is in need of a shot in the arm. UBS says CSL's Seqirus unit missed its 1H revenue forecast by 6% as U.S. demand weakened again. Analyst Laura Sutcliffe thinks elevated flu cases in FY 2025 will drive a recovery in immunization rates the following year, but probably not back to FY 2024 levels. "In general, margins tend to scale with sales in vaccines," UBS says. Government contracts for H5 (bird flu) pandemic readiness are a bright spot. UBS estimates revenue from these contracts at US$150 million in 2H, building on an estimated in US$60 million in 1H. Still, UBS believes the percentage drop in FY 2025 vaccine sales will be in the mid-to-high teens when these contracts are excluded. (david.winning@wsj.com; @dwinningWSJ)
(END) Dow Jones Newswires
February 11, 2025 17:30 ET (22:30 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。